Smart radiation therapy could make stem cell transplants safer for Non-Cancer patients
NCT ID NCT04083183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach to prepare patients with non-cancer blood diseases for a donor stem cell transplant. Instead of high-dose total body radiation, patients receive a radioactive antibody that targets blood-forming cells, aiming to reduce rejection and side effects. The trial involves 40 adults aged 18-50 and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Astatine-211-labeled anti-CD45 monoclonal antibody BC8-B10
- What this could lead to
- If it works, this could offer a safer way to prepare patients with non-cancer blood disorders for a stem cell transplant, reducing the need for total body radiation.
- What could go wrong
- This is an early phase 1/2 trial with only 40 participants, so results are preliminary. The radioactive antibody may cause side effects like organ damage or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States